stoxline Quote Chart Rank Option Currency Glossary
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
3.835  0.005 (0.13%)    12-01 16:00
Open: 3.99
High: 3.99
Volume: 229,515
Pre. Close: 3.83
Low: 3.78
Market Cap: 107(M)
Technical analysis
2023-12-01 4:22:28 PM
Short term     
Mid term     
Targets 6-month :  6.48 1-year :  7.94
Resists First :  5.55 Second :  6.8
Pivot price 4.55
Supports First :  3.52 Second :  2.93
MAs MA(5) :  3.92 MA(20) :  4.74
MA(100) :  4.6 MA(250) :  4.92
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  3.1 D(3) :  3.6
RSI RSI(14): 39.9
52-week High :  9.25 Low :  3.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RVPH ] has closed above bottom band by 24.1%. Bollinger Bands are 58.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.99 - 4.02 4.02 - 4.04
Low: 3.73 - 3.76 3.76 - 3.78
Close: 3.8 - 3.84 3.84 - 3.88
Company Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Headline News

Fri, 01 Dec 2023
Where Does Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Fall in the Biotechnology Field After It Has Fallen -15.57% This Week? - InvestorsObserver

Thu, 30 Nov 2023
Reviva Pharmaceuticals to Participate in The Benchmark ... - Yahoo Finance

Mon, 27 Nov 2023
Reviva Pharmaceuticals Holdings (RVPH) Price Target Increased by ... - Nasdaq

Mon, 20 Nov 2023
Retail investors among Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) largest stockholders and were hit after last week's 34% price drop - Simply Wall St

Fri, 17 Nov 2023
Walgreens stock drops as NYSE Healthcare Index sees mixed results - India

Fri, 17 Nov 2023
Healthcare Stocks Moving Up and Down Friday: FBIO, KOD, ITRM, TWST, VIGL, TNON, MAIA, RVPH - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 28 (M)
Shares Float 19 (M)
Held by Insiders 21.8 (%)
Held by Institutions 6 (%)
Shares Short 2,530 (K)
Shares Short P.Month 1,680 (K)
Stock Financials
EPS -1.68
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.38
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -158.4 %
Return on Equity (ttm) -636.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -2.29
PEG Ratio 0
Price to Book value -10.1
Price to Sales 0
Price to Cash Flow -4.44
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android